The Future of Glioblastoma Research:
Developing Clinically Relevant Models for Evaluating Novel Therapies
About this webinar
The blood-brain barrier (BBB) is a critical obstacle to developing brain-penetrant therapies for glioblastoma research and treatment. Orthotopic intracranial glioblastoma models (orthotopic means “the correct place”) are a next-generation platform that provide accurate preclinical data to inform lead candidate progression into the clinic.
During this webinar, the featured speaker will reveal innovations in glioblastoma model development and the future of glioblastoma research, diving into critical issues affecting glioblastoma drug development and how to overcome them. Attendees will review an in-depth case study on in vivo and in vitro strategies to model glioblastoma via 3D spheroid and orthotopic intracranial patient-derived xenograft (PDX) models. The speaker will also discuss the importance of selecting clinically relevant glioblastoma models that closely recapitulate human glioblastoma as well as specialized intracranial engraftment and dosing techniques.
Join this webinar to learn about the future of glioblastoma research and how to overcome challenges with glioblastoma drug development.
Who should attend
- Want to learn more about the current state of glioblastoma preclinical research and modelling
- Are seeking an experienced preclinical partner to conduct pharmacology studies for glioblastoma drug development and are looking to outsource rare and difficult intracranial engraftment procedures
What you will learn
- Innovations in glioblastoma model development and how to mitigate challenges in glioblastoma drug development
- The importance of selecting clinically relevant glioblastoma models that closely recapitulate human glioblastoma
- A case study on in vivo and in vitro strategies to model glioblastoma via 3D spheroid and orthotopic intracranial patient-derived xenograft (PDX) models
Featured Speakers
Monika Buczek, PhD
Dr. Buczek earned MPhil and PhD degrees in molecular, cellular and developmental Biology. She has extensive experience as a preclinical oncology scientific study director, specializing in in vitro, in vivo, orthotopic and humanized PDX studies, as well as hematological malignancies.
Partner for this event
Certis Oncology
Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence™ — highly predictive therapeutic response data derived from advanced biological models of cancer. Our proprietary platform informs individual treatment decisions and accelerates the development of new cancer therapies.
We partner with therapeutics developers to help close the problematic translation gap between preclinical studies and clinical trials. Certis brings greater certainty to go/no-go development decisions through more clinically relevant, well-characterized and annotated models combined with advanced imaging technology. Every preclinical study Certis designs with you is rooted in collaboration, scientific resolve, a bias for precision and a close connection to the patient.
Related webinars
More from Certis Oncology.
AI and Machine Learning with Advanced Preclinical Cancer Models for Improved Clinical Translation
AI in Cancer Research: Optimizing Biomarker Discovery, Model Selection, and Preclinical Decision-Making
Translational Research in Oncology — Innovations in Model Development